Selective and non-selective cyclooxygenase inhibitors delay stress fracture healing in the rat ulna

Journal of Orthopaedic Research

Volumn 31, Issue 2, 2013, Pages 235-242

  Kidd, Lisa J ^a   Cowling, Nick R ^a   Wu, Andy C ^b   Kelly, Wendy L ^b   Forwood, Mark R ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

cyclooxygenase 2; fracture healing; ibuprofen; NSAID; stress fracture

Indexed keywords

(5,5 DIMETHYL 3 3(3 FLUOROPHENYL) 4 (4 METHYLSULFONAL) PHENYL 2 (5H) FURANONE; ANTIINFLAMMATORY AGENT; IBUPROFEN; PMX 53; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE REMODELING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG EFFECT; FRACTURE HEALING; MORPHOMETRICS; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; RAT; STRESS FRACTURE; ULNA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE REMODELING; BONE RESORPTION; COMPLEMENT C5A; CYCLOOXYGENASE 2 INHIBITORS; FRACTURE HEALING; FRACTURES, BONE; FRACTURES, STRESS; FURANS; IBUPROFEN; OSTEOGENESIS; PEPTIDES, CYCLIC; RATS; RATS, WISTAR; ULNA;

EID: 84871611769     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.22203     Document Type: Article

References (55)

1. Mehallo CJ, Drezner JA, Bytomski JR,. 2006. Practical management: nonsteroidal antiinflammatory drug (NSAID) use in athletic injuries. Clin J Sport Med 16: 170-174.
2. Li L, Pettit AR, Gregory LS, et al. 2006. Regulation of bone biology by prostaglandin endoperoxide H synthases (PGHS): a rose by any other name. Cytokine Growth Factor Rev 17: 203-216.
3. Forwood MR,. 1996. Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11: 1688-1693.
4. Bo J, Sudmann E, Marton PF,. 1976. Effect of indomethacin on fracture healing in rats. Acta Orthop Scand 47: 588-599.
5. Allen HL, Wase A, Bear WT,. 1980. Indomethacin and aspirin: effect of nonsteroidal anti-inflammatory agents on the rate of fracture repair in the rat. Acta Orthop Scand 51: 595-600.
6. Altman RD, Latta LL, Keer R, et al. 1995. Effect of nonsteroidal antiinflammatory drugs on fracture healing: a laboratory study in rats. J Orthop Trauma 9: 392-400.
7. Endo K, Sairyo K, Komatsubara S, et al. 2005. Cyclooxygenase-2 inhibitor delays fracture healing in rats. Acta Orthop 76: 470-474.
8. Simon AM, O'Connor JP,. 2007. Dose and time-dependent effects of cyclooxygenase-2 inhibition on fracture-healing. J Bone Joint Surg Am 89: 500-511.
9. Li J, Waugh LJ, Hui SL, et al. 2007. Low-intensity pulsed ultrasound and nonsteroidal anti-inflammatory drugs have opposing effects during stress fracture repair. J Orthop Res 25: 1559-1567.
10. Bennell KL, Brukner PD,. 1997. Epidemiology and site specificity of stress fractures. Clin Sports Med 16: 179-196.
11. Iwamoto J, Takeda T,. 2003. Stress fractures in athletes: review of 196 cases. J Orthop Sci 8: 273-278.
12. Snyder RA, Koester MC, Dunn WR,. 2006. Epidemiology of stress fractures. Clin Sports Med 25: 37-52 viii.
13. Milgrom C, Giladi M, Stein M, et al. 1985. Stress fractures in military recruits. A prospective study showing an unusually high incidence. J Bone Joint Surg Br 67: 732-735.
14. Raasch WG, Hergan DJ,. 2006. Treatment of stress fractures: the fundamentals. Clin Sports Med 25: 29-36 vii.
15. Uthgenannt BA, Silva MJ,. 2007. Use of the rat forelimb compression model to create discrete levels of bone damage in vivo. J Biomech 40: 317-324.
16. Kidd LJ, Stephens AS, Kuliwaba JS, et al. 2010. Temporal pattern of gene expression and histology of stress fracture healing. Bone 46: 369-378.
17. Kidd LJ, Cowling NR, Wu AC, et al. 2011. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res 29: 1827-1833.
18. Gerstenfeld LC, Thiede M, Seibert K, et al. 2003. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res 21: 670-675.
19. Brown KM, Saunders MM, Kirsch T, et al. 2004. Effect of COX-2-specific inhibition on fracture-healing in the rat femur. J Bone Joint Surg Am 86-A: 116-123.
20. Monk PN, Scola AM, Madala P, et al. 2007. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol 152: 429-448.
21. Ting E, Guerrero AT, Cunha TM, et al. 2008. Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain. Br J Pharmacol 153: 1043-1053.
22. Woodruff TM, Strachan AJ, Sanderson SD, et al. 2001. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation 25: 171-177.
23. Haynes DR, Harkin DG, Bignold LP, et al. 2000. Inhibition of C5a-induced neutrophil chemotaxis and macrophage cytokine production in vitro by a new C5a receptor antagonist. Biochem Pharmacol 60: 729-733.
24. Woodruff TM, Strachan AJ, Dryburgh N, et al. 2002. Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum 46: 2476-2485.
25. Cenci S, Toraldo G, Weitzmann MN, et al. 2003. Estrogen deficiency induces bone loss by increasing T cell proliferation and lifespan through IFN-gamma-induced class II transactivator. Proc Natl Acad Sci USA 100: 10405-10410.
26. Riendeau D, Percival MD, Boyce S, et al. 1997. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor. Br J Pharmacol 121: 105-117.
27. Nicoll-Griffith DA, Falgueyret JP, Silva JM, et al. 1999. Oxidative bioactivation of the lactol prodrug of a lactone cyclooxygenase-2 inhibitor. Drug Metab Dispos 27: 403-409.
28. Hsieh YF, Silva MJ,. 2002. In vivo fatigue loading of the rat ulna induces both bone formation and resorption and leads to time-related changes in bone mechanical properties and density. J Orthop Res 20: 764-771.
29. Silva MJ, Touhey DC,. 2007. Bone formation after damaging in vivo fatigue loading results in recovery of whole-bone monotonic strength and increased fatigue life. J Orthop Res 25: 252-261.
30. Sample SJ, Hao Z, Wilson AP, et al. 2011. Role of calcitonin gene-related peptide in bone repair after cyclic fatigue loading. PLoS One 6: e20386.
31. Endo K, Sairyo K, Komatsubara S, et al. 2002. Cyclooxygenase-2 inhibitor inhibits the fracture healing. J Physiol Anthropol Appl Human Sci 21: 235-238.
32. Bergenstock M, Min W, Simon AM, et al. 2005. A comparison between the effects of acetaminophen and celecoxib on bone fracture healing in rats. J Orthop Trauma 19: 717-723.
33. Evans CE, Butcher C,. 2004. The influence on human osteoblasts in vitro of non-steroidal anti-inflammatory drugs which act on different cyclooxygenase enzymes. J Bone Joint Surg Br 86: 444-449.
34. Zhang X, Schwarz EM, Young DA, et al. 2002. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest 109: 1405-1415.
35. Alander CB, Raisz LG,. 2006. Effects of selective prostaglandins E2 receptor agonists on cultured calvarial murine osteoblastic cells. Prostaglandins Other Lipid Mediat 81: 178-183.
36. Arikawa T, Omura K, Morita I,. 2004. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J Cell Physiol 200: 400-406.
37. Simon AM, Manigrasso MB, O'Connor JP,. 2002. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 17: 963-976.
38. Lane N, Coble T, Kimmel DB,. 1990. Effect of naproxen on cancellous bone in ovariectomized rats. J Bone Miner Res 5: 1029-1035.
39. Gregory LS, Kelly WL, Reid RC, et al. 2006. Inhibitors of cyclo-oxygenase-2 and secretory phospholipase A2 preserve bone architecture following ovariectomy in adult rats. Bone 39: 134-142.
40. Bukata SV, Gelinas J, Wei X, et al. 2004. PGE2 and IL-6 production by fibroblasts in response to titanium wear debris particles is mediated through a Cox-2 dependent pathway. J Orthop Res 22: 6-12.
41. Lin SK, Kok SH, Kuo MY, et al. 2002. Sequential expressions of MMP-1, TIMP-1, IL-6, and COX-2 genes in induced periapical lesions in rats. Eur J Oral Sci 110: 246-253.
42. Zhang X, Morham SG, Langenbach R, et al. 2001. Evidence for a direct role of cyclo-oxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res 16: 660-670.
43. Chikazu D, Li X, Kawaguchi H, et al. 2002. Bone morphogenetic protein 2 induces cyclo-oxygenase 2 in osteoblasts via a Cbfal binding site: role in effects of bone morphogenetic protein 2 in vitro and in vivo. J Bone Miner Res 17: 1430-1440.
44. Rohde C, Anderson DE, Bertone AL, et al. 2000. Effects of phenylbutazone on bone activity and formation in horses. Am J Vet Res 61: 537-543.
45. Li J, Burr DB, Turner CH,. 2002. Suppression of prostaglandin synthesis with NS-398 has different effects on endocortical and periosteal bone formation induced by mechanical loading. Calcif Tissue Int 70: 320-329.
46. Hayden JM, Mohan S, Baylink DJ,. 1995. The insulin-like growth factor system and the coupling of formation to resorption. Bone 17: 93S-98S.
47. Gray C, Boyde A, Jones SJ,. 1996. Topographically induced bone formation in vitro: implications for bone implants and bone grafts. Bone 18: 115-123.
48. Smit TH, Burger EH, Huyghe JM,. 2002. A case for strain-induced fluid flow as a regulator of BMU-coupling and osteonal alignment. J Bone Miner Res 17: 2021-2029.
49. Martin TJ, Sims NA,. 2005. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11: 76-81.
50. Bakker AD, Klein-Nulend J, Burger EH,. 2003. Mechanotransduction in bone cells proceeds via activation of COX-2, but not COX-1. Biochem Biophys Res Commun 305: 677-683.
51. Okada Y, Lorenzo JA, Freeman AM, et al. 2000. Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105: 823-832.
52. Okada Y, Pilbeam C, Raisz L, et al. 2003. Role of cyclooxygenase-2 in bone resorption. J Uoeh 25: 185-195.
53. Karachalios T, Boursinos L, Poultsides L, et al. 2007. The effects of the short-term administration of low therapeutic doses of anti-COX-2 agents on the healing of fractures. An experimental study in rabbits. J Bone Joint Surg Br 89: 1253-1260.
54. Gerstenfeld LC, Al-Ghawas M, Alkhiary YM, et al. 2007. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J Bone Joint Surg Am 89: 114-125.
55. Gregory LS, Forwood MR,. 2007. Cyclooxygenase-2 inhibition delays the attainment of peak woven bone formation following four-point bending in the rat. Calcif Tissue Int 80: 176-183.